

[Skip to Main Content](#)[Skip to Footer](#)[Skip to Search](#)

SIGN UP NOW TO STAY CURRENT WITH THE LATEST NEWS AND INSIGHTS

[SUBSCRIBE NOW](#)

—

Regional Sites

[China](#)

[Japan](#)

[Latin America](#)

[Spanish](#)

[Portuguese](#)

—

Search for

Submit

—

# Catalent®

[Contact Us](#)

— — —

[Oral](#)

[Dose](#) —

[Development & Bioavailability](#) —

[Preclinical Development](#)

[Formulation](#)

[Bioavailability Enhancement](#)

[Integrated Development Solutions](#)

[OptiForm® Solution Suite](#)

[Catalent Xpress Pharmaceuticals®](#)

[ProteoSuite<sup>SM</sup> Oral](#)

[Dose Form Design](#) —

[OptiDose® Design Solution](#)

[Tablets & Capsules](#)

[Orally Disintegrating Tablets](#)

[Softgel Technology](#)

[Stick Pack](#)

Oral Technologies

Bioavailability Enhancement

Modified Release Formulations

Orally Disintegrating Tablets

Abuse Deterrent

Oral Macromolecule Delivery

Softgel Technologies

RP Scherer Softgel Technology

Plant Based Softgel Technology

Oral Macromolecule Delivery

Abuse Deterrent Technology

Smaller Easy to Swallow Softgels

Oral Manufacturing

Commercial Manufacturing

Scale-Up & Product Launch

Technology Transfers

OneXpress™ Solution

Oral Dose Packaging

Oral Dose Analytical Solutions

Solid-State Characterization Services

Methods Development & Validation

Stability Testing & Storage

Nitrosamine Testing Services

Highly Potent Active Pharmaceutical Ingredients

Biologics

Biotherapeutics

Advanced Therapeutics

Specialty

Technologies

Specialty

Inhalation

Inhalation Development & Analytical

Nasal Delivery

Dry Powder Inhalers

Small Molecule Injectable

Regulatory Support Services

Orphan Drugs

Emerging Biotech Solutions

Clinical

Supply

Forecasting & Planning

Packaging Services

Comparator Sourcing

Distribution & Logistics

Consumer

Over-The-Counter

Nutritional Supplements

Beauty

Product Library

Expert

Content

Biologics

Clinical Supply Services

Consumer Health

Cell Therapy

Gene Therapy

Development & Bioavailability

Dose Form Design

Inhalation

Oral Manufacturing

Oral Technologies

Small Molecule Analytical

Small Molecule Injectable

Softgel Technologies

Locations

Asia Pacific

Europe

Latin America

North America

Site Tours

[About Us](#) 

[Who We Are](#)

[News & Events](#)

[Our Leadership](#)

[Our Scientists](#)

[Investors](#)

[Corporate Responsibility](#)

[Diversity & Inclusion](#)

[Careers](#)

[Contact Us](#)

### Main menu



[Oral Dose](#) 

[Development & Bioavailability](#) 

[Preclinical Development](#)

[Formulation](#)

[Bioavailability Enhancement](#)

[Integrated Development Solutions](#)

[OptiForm® Solution Suite](#)

[Catalent Xpress Pharmaceuticals®](#)

[ProteoSuite<sup>SM</sup> Oral](#)

[Dose Form Design](#) 

[OptiDose® Design Solution](#)

[Tablets & Capsules](#)

[Orally Disintegrating Tablets](#)

[Softgel Technology](#)

[Stick Pack](#)

[Oral Technologies](#) 

[Bioavailability Enhancement](#)

[Modified Release Formulations](#)

[Orally Disintegrating Tablets](#)

[Abuse Deterrent](#)

[Oral Macromolecule Delivery](#)

[Softgel Technologies](#) 

[RP Scherer Softgel Technology](#)

Plant Based Softgel Technology  
Oral Macromolecule Delivery  
Abuse Deterrent Technology  
Smaller Easy to Swallow Softgels  
Oral Manufacturing   
Commercial Manufacturing  
Scale-Up & Product Launch  
Technology Transfers  
OneXpress™ Solution  
Oral Dose Packaging  
Oral Dose Analytical Solutions   
Solid-State Characterization Services  
Methods Development & Validation  
Stability Testing & Storage  
Nitrosamine Testing Services  
Highly Potent Active Pharmaceutical Ingredients  
Biologics   
Biotherapeutics  
Advanced Therapeutics  
Specialty  
Technologies  
Specialty   
Inhalation   
Inhalation Development & Analytical  
Nasal Delivery  
Dry Powder Inhalers  
Small Molecule Injectable  
Regulatory Support Services  
Orphan Drugs  
Emerging Biotech Solutions  
Clinical Supply   
Forecasting & Planning  
Packaging Services  
Comparator Sourcing  
Distribution & Logistics

Consumer

Over-The-Counter

Nutritional Supplements

Beauty

Product Library

Expert Content

Biologics

Clinical Supply Services

Consumer Health

Cell Therapy

Gene Therapy

Development & Bioavailability

Dose Form Design

Inhalation

Oral Manufacturing

Oral Technologies

Small Molecule Analytical

Small Molecule Injectable

Softgel Technologies

Locations

Asia Pacific

Europe

Latin America

North America

Site Tours

About Us

Who We Are

News & Events

Our Leadership

Our Scientists

Investors

Corporate Responsibility

Diversity & Inclusion

Careers

Regional Sites



[China](#)

[Japan](#)

[Latin America](#)

[Spanish](#)

[Portuguese](#)

1. [Home](#)

»

2. [About Us](#)

»

3. [Our Leadership](#)

» [Frank A. D'Amelio](#)

# Frank A. D'Amelio



**FRANK A. D'AMELIO**  
**BOARD MEMBER**

**Frank D'Amelio has been a board member since August 2023.** Mr. D'Amelio is the former Chief

Financial Officer and Executive Vice President, Global Supply, of Pfizer Inc. where he was responsible for all corporate finance functions including audit, controllers, tax, and treasury as well as global supply.

Prior to joining Pfizer, Mr. D'Amelio served as Senior Executive Vice President of Integration and Chief Administrative Officer of Alcatel-Lucent, responsible for the 2006 Alcatel-Lucent merger as well as procurement, real estate, IT, and supply chain. Prior to that, Mr. D'Amelio was the Chief Operating Officer of Lucent Technologies, responsible for leading business operations, including sales, the product groups, the services business, the supply chain, information technology operations, human resources, and labor relations. In 2001, he was appointed Executive Vice President and Chief Financial Officer of Lucent. In addition, Mr. D'Amelio held a number of roles while at Lucent Technologies, and before that, served in a variety of positions while at AT&T, including CFO, Transmission Systems and Controller, Network Systems.

Mr. D'Amelio has served on the Board of Directors of Humana since September 2003, where he currently serves as Chair of the Audit Committee, on the Board of Directors of Zoetis, Inc. since July 2012, and on the Board of Directors of Hewlett Packard Enterprise since January 2023. He currently serves as a CFO in residence at the Deloitte CFO Academy.

Mr. D'Amelio holds an M.B.A. in Finance from St. John's University and a bachelor's degree in Accounting from St. Peter's College.

[Expert Content](#) [Subscribe](#) [Investors](#) [Careers](#) [Contact Us](#) [Site Map](#)

Follow Us. Share Us.

By using this website you understand and accept that Catalent tracks your website activities to be able to offer you a more tailored response or information to meet your requirements, and that your personal data will be held in accordance with our [Privacy Policy](#) | [Data Privacy Framework Statement](#) | [Cookies Settings](#).

Copyright 2024, Catalent, Inc - All Rights Reserved

[Terms](#) [Modern Slavery Statement](#)